Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report Puts Patients at the Center
- Jazz Pharmaceuticals focuses on developing life-changing medicines for patients with serious diseases
- None.
Originally published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report
NORTHAMPTON, MA / ACCESSWIRE / October 6, 2023 / A Letter From Our Chairman of the Board and Chief Executive Officer Bruce C. Cozadd
I am pleased to share Jazz's 2022 Corporate Sustainability and Social Impact Report.
Jazz's core mission centers on developing life-changing medicines for people with serious diseases - often with limited or no options - so they can live their lives more fully. Over our 20-year history, we have expanded our capabilities, significantly diversified our neuroscience and oncology product portfolios and increased our impact across the globe. We put patients at the center of everything we do and strive to better understand where we can make the greatest difference for our patients and their families. Our patient-first approach is reflected in our Corporate Sustainability and Social Impact (CSSI) strategy. Underpinned by our CSSI pillars: Patients, People, Community and Planet, we are committed to maximizing our positive impact on our people and society while ensuring we minimize Jazz's impact on the environment.
Last year, we provided Vision 2025 as a clear path of how we plan to build a sustainable business that delivers important new therapies for patients and enhanced value for shareholders. In addition, we took a key step forward in conducting a materiality assessment to identify and prioritize Jazz's material topics so that our CSSI strategy aligned with and reflected our corporate strategy, business operations and the priorities of our stakeholders. We engaged with employees across our geographies and business units, members of the leadership team, investors, suppliers, advocacy groups and nongovernmental organizations (NGOs) to ensure we captured their views. The outcomes of this assessment will serve as the basis of our multi-year CSSI priorities and strategy.
We are proud of the progress made in 2022 toward initiatives within each of our CSSI pillars.
We executed on our mission of bringing treatments and hope to people living with difficult-to-treat conditions. We enhanced the breadth and depth of our pipeline, added three promising candidates while expanding into disease areas with significant unmet patient need and progressed multiple preclinical and clinal-stage programs. As we continue to uncover and rectify treatment disparities across patient populations, our team conducted ethnographic research furthering our commitment toward equitable access to our therapies.
We exemplified our commitment to being a great place to work by living our core values of Integrity, Collaboration, Passion, Innovation and Pursuit of Excellence. Our people are critical to ensuring we can best serve our patients. I am proud of the engagement of our employees, who continuously exceed a
As engaged corporate citizens working through direct philanthropy and employee volunteerism, we expanded our understanding of the needs of our global, local and patient communities. In 2022, we launched a company-wide Global Volunteer Day, provided mentorship to students interested in pursuing healthcare careers and we offered pro bono legal and other services to promote healthy and well-functioning societies.
We are proud of the improvements made to reduce our environmental footprint. Our Athlone manufacturing site purchases
Throughout 2023, we continue to make progress toward Vision 2025, while building upon our previous environmental, social and governance materiality assessments and further embedding our CSSI strategy into the work we do. We recognize that the success of any strategy, sustainability or otherwise, will be inextricably linked to targets and objectives, which are a core component of driving accountability throughout the business. As we advance our CSSI strategy this year, we will continue to integrate our ambitions, goals and initiatives into our strategic vision.
We believe that positively impacting patients' lives, investing in our people and our commitment to long-term sustainability are important components of delivering on Vision 2025. We look forward to continuing to innovate for our patients while implementing our CSSI strategy to generate long-term sustainable value.
Read more of Jazz's 2022 Corporate Sustainability and Social Impact Report here.
View additional multimedia and more ESG storytelling from Jazz Pharmaceuticals on 3blmedia.com.
Contact Info:
Spokesperson: Jazz Pharmaceuticals
Website: https://www.3blmedia.com/profiles/jazz-pharmaceuticals
Email: info@3blmedia.com
SOURCE: Jazz Pharmaceuticals
View source version on accesswire.com:
https://www.accesswire.com/790788/jazz-pharmaceuticals-2022-corporate-sustainability-and-social-impact-report-puts-patients-at-the-center
FAQ
What is Jazz Pharmaceuticals' core mission?
What are the pillars of Jazz's Corporate Sustainability and Social Impact strategy?
What progress did Jazz make in 2022?
What is Vision 2025?
What is the contact information for Jazz Pharmaceuticals?
